MedTrace Logo

Prospective Trial for the Evaluation of Radiogenomics in Advanced Rectal Cancer

NCT04287400 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2021-09-05

No results posted yet for this study

Summary

In patients with advanced rectal cancer, molecular subtypes will be identified by preoperative biopsy, CT, MRI / PET radiomics analysis, clinical features, and clinical features will be confirmed and compared.

Also, we want to confirm the relationship between these factors and the treatment response after chemoradiotherapy before surgery. The prognosis will be then assessed through 5-year overall survival and 3-year disease free survival.

A prospective clinical trial, recruiting 210 persons (approximately 53 per year) that meet the selection criteria for approximately four years from the IRB approval date in 2019 (about 53 per year) We will analyze the data and then collect and analyze the data and report the results.

Conditions

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2022-12-01
Completion
2025-12-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287400 on ClinicalTrials.gov